Serum Adropin Levels in Patients on Hemodialysis.

Adropin is a novel pleotropic peptide involved in energy homeostasis, with possible contribution to cardiovascular protection through production of nitric oxide and subsequent blood pressure regulation. Given that patients undergoing hemodialysis (HD) are related with high cardiovascular risk, hyperlipidemia, chronic low-grade inflammation, and malnutrition the aim of our study was to investigate serum adropin levels in HD patients to evaluate possible associations with nutritional status and other relevant clinical and laboratory parameters. The study included 70 patients on HD and 60 healthy controls. Serum adropin levels were determined by an enzyme-linked immunosorbent assay in a commercially available diagnostic kit. Serum adropin levels were significantly lower in the HD group compared to the control group (2.20 ± 0.72 vs. 4.05 ± 0.93 ng/mL, < 0.001). Moreover, there was a significant negative correlation with malnutrition-inflammation score (r = -0.476, < 0.001), dialysis malnutrition score (r = -0.350, = 0.003), HD duration (r = -0.305, = 0.010), and high sensitivity C-reactive protein (hsCRP) (r = -0.646, < 0.001). Additionally, there was a significant negative correlation between adropin levels and pre-dialysis systolic (r = -0.301, = 0.011) and diastolic blood pressure (r = -0.299, = 0.011). These results are implying that adropin is potentially involved in the pathophysiological mechanisms of chronic kidney disease (CKD)/HD and its complications. However, future larger scale longitudinal studies need to further address it.